Bryostatin and Vincristine in B-Cell Malignancies

Inclusion Criteria:

• Patients with biopsy proven B-cell malignancies [e.g. chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), multiple myeloma (MM)]; HIV-associated lymphomas and acute leukemias are not eligible
• Performance status: ECOG 0, 1, or 2
• Life expectancy of at least 12 weeks
• Patients with aggressive NHL will be enrolled after having failed all possible therapy with curative intent
• Patients with CLL must have failed an alkylating agent-containing regimen as well as fludarabine chemotherapy
• Patients with multiple myeloma must have received at least one prior chemotherapy regimen and not be eligible for a dose intensification treatment approach
• At least 4 weeks must have elapsed since prior large-field radiation therapy
• Patients must have been off previous anti-cancer therapy for at least 3 weeks (6 weeks for BCNU and mitomycin C) and recovered from all treatment related toxicity
• Prior vincristine therapy is allowed
• Sexually active men and women must use an accepted and effective method of contraception
• In women of child-bearing age, a pregnancy test may be done at the discretion of the investigator
• Must have given written informed consent

Exclusion Criteria:

• Patients with brain metastasis, leptomeningeal involvement, primary CNS NHL, and acute leukemia are ineligible
• Patients with HIV infection are ineligible
• WBC < 3000/ul
• Granulocytes < 1500/ul
• Platelets < 50,000/ul
• Hemoglobin =< 8.5 g/dl
• Bilirubin > 1.5 mg/dl
• AST and ALT > 2 times normal
• Creatinine > 2.0 mg/dl, and/or actual creatinine clearance < 40 ml/min/1.73 m^2; all patients are required to have a 24 hr creatinine clearance
• Clinical evidence of bleeding diathesis
• ECOG Performance status 3 or 4
• Patients who are pregnant or lactating; vincristine can cause fetal harm
• Patients with clinically apparent neuropathy are ineligible (>= grade 2 neuropathy)